Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene Explodes 28% After-Hours On Initial ALLO-501 Data
08:20am, Thursday, 14'th May 2020
On Wednesday, Allogene (ALLO) revealed positive initial data from its ALLO-501 CD19 allogeneic CAR T, showing both activity and a tolerable safety profile. The news sent shares surging 28% in Wednesda
Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline
12:00am, Thursday, 14'th May 2020
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that the company will present data from its expanding oncology p
ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host DiseaseAbstract Based on.
Will Allogene Therapeutics Continue to Surge Higher?
02:54pm, Wednesday, 13'th May 2020
As of late, it has definitely been a great time to be an investor Allogene Therapeutics
CASI Pharmaceuticals: 2-Year Price Lows Make For Intriguing Risk-On Buy
02:27am, Wednesday, 13'th May 2020
CASI is focused on developing and commercialising drugs for the Chinese market most notably within the field of hematology/oncology using an innovative in-licen
Seattle Genetics Highlights Data from Expanding Oncology Portfolio During Virtual Scientific Program of the 2020 ASCO Annual Meeting
12:00am, Wednesday, 13'th May 2020
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the presentation of new data from its expanding pipeline of marketed and investigational therapie
2020 Insights on the Worldwide Induced Pluripotent Stem Cell Industry - ResearchAndMarkets.com
12:00am, Tuesday, 12'th May 2020
The
How Allogene (ALLO) Stock Stands Out in a Strong Industry
12:30pm, Monday, 11'th May 2020
Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Cellectis' (CLLS) CEO André Choulika on Q1 2020 Results - Earnings Call Transcript
08:51am, Saturday, 09'th May 2020
Cellectis S.A. (NASDAQ:CLLS) Q1 2020 Earnings Conference Call May 7, 2020 7:30 AM ET Company Participants Simon Harnest – Vice President-Corporate Strategy and
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2020 Results - Earnings Call Transcript
05:16am, Saturday, 09'th May 2020
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2020 Earnings Conference Call May 6, 2020 08:30 ET Company Participants Christine Cassiano - Chief Communications O
U.S. RESEARCH ROUNDUP-Ashland Global, Lyft, Solaredge Technologies
03:19pm, Thursday, 07'th May 2020
Wall Street securities analysts on Thursday revised their ratings and
price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and
Solaredge Technologies.
HIGH
Allogene Therapeutics Inc (ALLO) Q1 2020 Earnings Call Transcript
12:01pm, Thursday, 07'th May 2020
ALLO earnings call for the period ending March 31, 2020.
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
12:00am, Thursday, 07'th May 2020
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
Cellectis : publie ses résultats financiers du premier trimestre 2020 | Zone bourse
08:45pm, Wednesday, 06'th May 2020Pandemic leads R&A to break with tradition over captaincy
07:54pm, Wednesday, 06'th May 2020
The COVID-19 pandemic has led the Royal & Ancient Golf Club of St Andrews to break with tradition and nominate, for only the second time in 266 years, its captain to serve for two successive terms.
